[{"id":"5946fd69-e35c-4966-a99b-d42d265fb810","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505813","created_at":"2021-03-12T18:53:10.090Z","updated_at":"2024-07-02T16:35:23.473Z","phase":"Phase 1/2","brief_title":"Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma","source_id_and_acronym":"NCT04505813","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A","pipe":"","alterations":" ","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NEXI-002"],"overall_status":"Suspended","enrollment":" Enrollment 9","initiation":"Initiation: 08/17/2020","start_date":" 08/17/2020","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-15"}]